» Articles » PMID: 11801191

A Cohort Study of Possible Risk Factors for Over-reporting of Antihypertensive Adherence

Overview
Publisher Biomed Central
Date 2002 Jan 22
PMID 11801191
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The identification of poor medicinal adherence is difficult because direct observation of medication use is usually impractical. Up to 50% of individuals on chronic therapies may not be taking their medication as prescribed. This study is one of the first to explore possible risk factors for over-reporting of antihypertensive adherence using electronic medication monitoring.

Methods: The adherence of 286 individuals on single-drug antihypertensive therapy in a large managed care organization was electronically monitored for approximately three months. Questionnaires on socioeconomic background, adherence to therapy, health beliefs, and social support before and after adherence monitoring were completed. Over-reporting of antihypertensive adherence was assessed by comparing the self-reported frequency of noncompliance with that determined from electronic dosing records. Risk factors for over-reporting were identified by contingency table analysis and step-wise logistic regression.

Results: Although only 21% of participants acknowledged missing doses on one or more days per week, electronic monitoring documented nonadherence at this or a higher level in 42% of participants. The following variables were associated with over-reporting: >1 versus 1 daily dose (OR = 2.58; 95% CI = 1.50-4.41; p =.0006), lower perceived health risk from nonadherence (OR = 1.35; 95% CI = 1.10-1.64; p =.0035), and annual household income of <15,000 dollars versus >30,000 dollars (OR = 2.64; 95% CI = 1.13-6.18; p =.025).

Conclusions: Over-reporting of adherence may be affected by factors related to dosing frequency, health beliefs and socioeconomic status. This topic deserves further investigation in other patient populations to elucidate possible underlying behavioral explanations.

Citing Articles

Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study.

Lopes S, Pericot-Valverde I, Lum P, Taylor L, Mehta S, Tsui J BMC Infect Dis. 2024; 24(1):251.

PMID: 38395747 PMC: 10893697. DOI: 10.1186/s12879-024-09124-3.


Memory complaints moderate the concordance between self-report and electronically monitored adherence in adults with type 2 diabetes.

Shapira A, Kane N, Tanenbaum M, Hoogendoorn C, Gonzalez J J Diabetes Complications. 2022; 36(7):108205.

PMID: 35667963 PMC: 10290887. DOI: 10.1016/j.jdiacomp.2022.108205.


Ethical considerations in adherence research.

Patel N, Moore B, Craver R, Feldman S Patient Prefer Adherence. 2016; 10:2429-2435.

PMID: 27980394 PMC: 5147396. DOI: 10.2147/PPA.S117802.


Factors associated with false-positive self-reported adherence to antihypertensive drugs.

Tedla Y, Bautista L J Hum Hypertens. 2016; 31(5):320-326.

PMID: 27853149 PMC: 6062205. DOI: 10.1038/jhh.2016.80.


A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence.

El Alili M, Vrijens B, Demonceau J, Evers S, Hiligsmann M Br J Clin Pharmacol. 2016; 82(1):268-79.

PMID: 27005306 PMC: 4917812. DOI: 10.1111/bcp.12942.


References
1.
Steiner J, Koepsell T, Fihn S, Inui T . A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988; 26(8):814-23. DOI: 10.1097/00005650-198808000-00007. View

2.
Morisky D, Green L, Levine D . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1):67-74. DOI: 10.1097/00005650-198601000-00007. View

3.
Cramer J, Mattson R, Prevey M, Scheyer R, Ouellette V . How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989; 261(22):3273-7. View

4.
Maronde R, Chan L, Larsen F, Strandberg L, Laventurier M, Sullivan S . Underutilization of antihypertensive drugs and associated hospitalization. Med Care. 1989; 27(12):1159-66. DOI: 10.1097/00005650-198912000-00007. View

5.
Psaty B, Koepsell T, Wagner E, LoGerfo J, Inui T . The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990; 263(12):1653-7. View